Cancer immunotherapy has shown remarkable results in various cancer types through a range of immunotherapeutic approaches, including chimeric antigen receptor‐T cell (CAR‐T) ther-apy, immune checkpoint blockade (ICB), and therapeutic vaccines. Despite the enormous potential of cancer immunotherapy, its application in various clinical settings has been limited by immune evasion and immune suppressive mechanisms occurring locally or systemically, low durable response rates, and severe side effects. In the last decades, the rapid advancement of nanotechnology has been aiming at the development of novel synthetic nanocarriers enabling precise and enhanced delivery of immunotherapeutics, while improving drug stability and effectiveness. Magnetic nanostructured formulations are particularly intriguing because of their easy surface functionaliza-tion, low cost, and robust manufacturing procedures, together with their suitability for the imple-mentation of magnetically‐guided and heat‐based therapeutic strategies. Here, we summarize and discuss the unique features of magnetic‐based nanostructures, which can be opportunely designed to potentiate classic immunotherapies, such as therapeutic vaccines, ICB, adoptive cell therapy (ACT), and in situ vaccination. Finally, we focus on how multifunctional magnetic delivery systems can facilitate the anti‐tumour therapies relying on multiple immunotherapies and/or other therapeutic modalities. Combinatorial magnetic‐based therapies are indeed offering the possibility to overcome current challenges in cancer immunotherapy.

Magnetic nanostructures as emerging therapeutic tools to boost anti‐tumour immunity / S. Persano, P. Das, T. Pellegrino. - In: CANCERS. - ISSN 2072-6694. - 13:11(2021 May), pp. 2735.1-2735.31. [10.3390/cancers13112735]

Magnetic nanostructures as emerging therapeutic tools to boost anti‐tumour immunity

S. Persano
Primo
;
T. Pellegrino
Ultimo
2021

Abstract

Cancer immunotherapy has shown remarkable results in various cancer types through a range of immunotherapeutic approaches, including chimeric antigen receptor‐T cell (CAR‐T) ther-apy, immune checkpoint blockade (ICB), and therapeutic vaccines. Despite the enormous potential of cancer immunotherapy, its application in various clinical settings has been limited by immune evasion and immune suppressive mechanisms occurring locally or systemically, low durable response rates, and severe side effects. In the last decades, the rapid advancement of nanotechnology has been aiming at the development of novel synthetic nanocarriers enabling precise and enhanced delivery of immunotherapeutics, while improving drug stability and effectiveness. Magnetic nanostructured formulations are particularly intriguing because of their easy surface functionaliza-tion, low cost, and robust manufacturing procedures, together with their suitability for the imple-mentation of magnetically‐guided and heat‐based therapeutic strategies. Here, we summarize and discuss the unique features of magnetic‐based nanostructures, which can be opportunely designed to potentiate classic immunotherapies, such as therapeutic vaccines, ICB, adoptive cell therapy (ACT), and in situ vaccination. Finally, we focus on how multifunctional magnetic delivery systems can facilitate the anti‐tumour therapies relying on multiple immunotherapies and/or other therapeutic modalities. Combinatorial magnetic‐based therapies are indeed offering the possibility to overcome current challenges in cancer immunotherapy.
Cancer immunotherapy; Combinatorial immunotherapy; Immune therapeu-tics; Immunogenic cell death; Magnetic nanostructures; Surface chemistry; Vaccines
Settore BIO/13 - Biologia Applicata
   HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields
   HyperCube
   European Commission
   Horizon 2020 Framework Programme
   899661

   Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment
   MHT-ImmunoEnhancer
   European Commission
   Horizon 2020 Framework Programme
   843838
mag-2021
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/958898
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 20
social impact